Regional Hepatic Chemotherapies in Treatment of Colorectal Cancer Metastases to the Liver

Seminars in Oncology

Volumn 37, Issue 2, 2010, Pages 139-148

  Ammori, John B ^a   Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISCHLORETHYLNITROSUREA; DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTERITIS; ARTICLE; BILIARY TRACT DISEASE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATOBILIARY DISEASE; HUMAN; IMMUNOTHERAPY; LIVER METASTASIS; LIVER SURGERY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 77952400619     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.03.003     Document Type: Article

References (60)

1. American Cancer Society. http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_statistics_for_colon_and_rectum_cancer.asp Accessed November 27, 2009
2. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318
3. Rees M., Tekkis P.P., Welsh F.K., O'Rourke T., and John T.G. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247 (2008) 125-135
4. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235 (2002) 759-766
5. Abdalla E.K., Adam R., Bilchik A.J., Jaeck D., Vauthey J.N., and Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13 (2006) 1271-1280
6. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
7. Breedis C., and Young G. The blood supply of neoplasms in the liver. Am J Pathol 30 (1954) 969-977
8. Ackerman N.B. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75 (1974) 589-596
9. Sigurdson E.R., Ridge J.A., Kemeny N., and Daly J.M. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5 (1987) 1836-1840
10. Ensminger W.D., and Gyves J.W. Regional chemotherapy of neoplastic diseases. Pharmacol Ther 21 (1983) 277-293
11. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341 (1999) 2039-2048
12. Allen P.J., Nissan A., Picon A.I., et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 201 (2005) 57-65
13. Curley S.A., Chase J.L., Roh M.S., and Hohn D.C. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 114 (1993) 928-935
14. Ensminger W.D., and Gyves J.W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10 (1983) 176-182
15. Wagner J.G., Gyves J.W., Stetson P.L., et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46 (1986) 1499-1506
16. Dzodic R., Gomez-Abuin G., Rougier P., et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 15 (2004) 647-650
17. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23 (2005) 4881-4887
18. van Riel J.M., van Groeningen C.J., de Greve J., Gruia G., Pinedo H.M., and Giaccone G. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 15 (2004) 59-63
19. Gluck W.L., Akwari O.E., Kelvin F.M., and Goodwin B.J. A reversible enteropathy complicating continuous hepatic artery infusion chemotherapy with 5-fluoro-2-deoxyuridine. Cancer 56 (1985) 2424-2427
20. Northover J.M., and Terblanche J. A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 66 (1979) 379-384
21. Skitzki J.J., and Chang A.E. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol 11 (2002) 123-135
22. Kemeny N., Daly J., Oderman P., et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 2 (1984) 595-600
23. Kemeny N., Seiter K., Niedzwiecki D., et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 69 (1992) 327-334
24. Stagg R.J., Venook A.P., Chase J.L., et al. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 83 (1991) 423-428
25. Davidson B.S., Izzo F., Chase J.L., et al. Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Am J Surg 172 (1996) 244-247
26. Kemeny N.E., Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27 (2009) 3465-3471
27. Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., and Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344 (1994) 1255-1260
28. Chang A.E., Schneider P.D., Sugarbaker P.H., Simpson C., Culnane M., and Steinberg S.M. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206 (1987) 685-693
29. Hohn D.C., Stagg R.J., Friedman M.A., et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7 (1989) 1646-1654
30. Kemeny N., Daly J., Reichman B., Geller N., Botet J., and Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107 (1987) 459-465
31. Kemeny N.E., Niedzwiecki D., Hollis D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24 (2006) 1395-1403
32. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361 (2003) 368-373
33. Lorenz M., and Muller H.H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18 (2000) 243-254
34. Martin Jr. J.K., O'Connell M.J., Wieand H.S., et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125 (1990) 1022-1027
35. Rougier P., Laplanche A., Huguier M., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10 (1992) 1112-1118
36. Wagman L.D., Kemeny M.M., Leong L., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8 (1990) 1885-1893
37. Goldberg R.M., Sargent D.J., Morton R.F., et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24 (2006) 3347-3353
38. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
39. Fiorentini G., Cantore M., Rossi S., et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo 20 (2006) 707-709
40. Rothenberg M.L., Cox J.V., Butts C., et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19 (2008) 1720-1726
41. Shitara K., Munakata M., Kudo T., et al. Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer. Gan To Kagaku Ryoho 33 (2006) 2033-2037
42. Gallagher D.J., Capanu M., Raggio G., and Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 18 (2007) 1995-1999
43. Kemeny N., Gonen M., Sullivan D., et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19 (2001) 2687-2695
44. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23 (2005) 4888-4896
45. Barone C., Nuzzo G., Cassano A., et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97 (2007) 1035-1039
46. Tabernero J., Van Cutsem E., Diaz-Rubio E., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25 (2007) 5225-5232
47. Boige V., Malka D., Elias D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15 (2008) 219-226
48. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239 (2004) 818-825
49. Muratore A., Polastri R., Bouzari H., Vergara V., Ferrero A., and Capussotti L. Repeat hepatectomy for colorectal liver metastases: a worthwhile operation?. J Surg Oncol 76 (2001) 127-132
50. Topal B., Kaufman L., Aerts R., and Penninckx F. Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol 29 (2003) 248-253
51. Kemeny N.E., and Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 352 (2005) 734-735
52. Kemeny M.M., Adak S., Gray B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 20 (2002) 1499-1505
53. Lygidakis N.J., Ziras N., and Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 42 (1995) 155-161
54. Lygidakis N.J., Sgourakis G., Vlachos L., et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 48 (2001) 1685-1691
55. Lorenz M., Muller H.H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228 (1998) 756-762
56. Kemeny N., Jarnagin W., Gonen M., et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 21 (2003) 3303-3309
57. Kemeny N., Capanu M., D'Angelica M., et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 20 (2009) 1236-1241
58. Ito H., Are C., Gonen M., et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 247 (2008) 994-1002
59. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25 (2007) 4575-4580
60. House MG, Kemeny N, Jarnagin W, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco; January 17, 2009.